BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 21239357)

  • 21. Fixed dose-rate infusion of gemcitabine in combination with cisplatin and UFT in advanced carcinoma of the pancreas.
    Feliu J; Sáenz JG; Jaráiz AR; Castañón C; Cruz M; Fonseca E; Lomas M; Castro J; Jara C; Casado E; León A; Barón MG
    Cancer Chemother Pharmacol; 2006 Oct; 58(4):419-26. PubMed ID: 16404636
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Combination chemotherapy with gemcitabine and S-1 for advanced pancreatic cancer].
    Nakamura K; Yamaguchi T; Sudo K; Ishihara T; Saisho H
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():219-23. PubMed ID: 16898006
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma-TCOG T1211 study.
    Chiang NJ; Tsai KK; Hsiao CF; Yang SH; Hsiao HH; Shen WC; Hsu C; Lin YL; Chen JS; Shan YS; Chen LT
    Eur J Cancer; 2020 Jan; 124():123-130. PubMed ID: 31765987
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I clinical trial of oral administration of S-1 in combination with intravenous gemcitabine and cisplatin in patients with advanced biliary tract cancer.
    Shoji H; Morizane C; Sakamoto Y; Kondo S; Ueno H; Takahashi H; Ohno I; Shimizu S; Mitsunaga S; Ikeda M; Okusaka T
    Jpn J Clin Oncol; 2016 Feb; 46(2):132-7. PubMed ID: 26685318
    [TBL] [Abstract][Full Text] [Related]  

  • 25. S-1 and gemcitabine as an outpatient-based regimen in patients with advanced or metastatic pancreatic cancer.
    Kim MK; Lee KH; Jang BI; Kim TN; Eun JR; Bae SH; Ryoo HM; Lee SA; Hyun MS
    Jpn J Clin Oncol; 2009 Jan; 39(1):49-53. PubMed ID: 19060295
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial.
    Hammel P; Fabienne P; Mineur L; Metges JP; Andre T; De La Fouchardiere C; Louvet C; El Hajbi F; Faroux R; Guimbaud R; Tougeron D; Bouche O; Lecomte T; Rebischung C; Tournigand C; Cros J; Kay R; Hamm A; Gupta A; Bachet JB; El Hariry I
    Eur J Cancer; 2020 Jan; 124():91-101. PubMed ID: 31760314
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II study of gemcitabine, UFT and leucovorin in patients with advanced pancreatic cancer.
    Kim TW; Kang HJ; Ahn JH; Lee K; Chang HM; Kang YK; Lee JS
    Acta Oncol; 2002; 41(7-8):689-94. PubMed ID: 14651215
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.
    Philip PA; Lacy J; Portales F; Sobrero A; Pazo-Cid R; Manzano Mozo JL; Kim EJ; Dowden S; Zakari A; Borg C; Terrebonne E; Rivera F; Sastre J; Bathini V; López-Trabada D; Asselah J; Saif MW; Shiansong Li J; Ong TJ; Nydam T; Hammel P
    Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):285-294. PubMed ID: 31953079
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.).
    Gebbia V; Majello E; Testa A; Pezzella G; Giuseppe S; Giotta F; Riccardi F; Fortunato S; Colucci G; Gebbia N
    Cancer; 1996 Sep; 78(6):1300-7. PubMed ID: 8826954
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer.
    Kanai M; Yoshimura K; Asada M; Imaizumi A; Suzuki C; Matsumoto S; Nishimura T; Mori Y; Masui T; Kawaguchi Y; Yanagihara K; Yazumi S; Chiba T; Guha S; Aggarwal BB
    Cancer Chemother Pharmacol; 2011 Jul; 68(1):157-64. PubMed ID: 20859741
    [TBL] [Abstract][Full Text] [Related]  

  • 31. S-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer.
    Ke QH; Zhou SQ; Yang JY; Du W; Liang G; Lei Y; Luo F
    World J Gastroenterol; 2014 Oct; 20(38):13987-92. PubMed ID: 25320537
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modified FOLFIRINOX for Locally Advanced and Metastatic Pancreatic Cancer Patients Resistant to Gemcitabine and S-1 in Japan: A Single Institutional Experience.
    Umemura A; Nitta H; Sasaki A; Takahara T; Hasegawa Y; Wakabayashi G
    Hepatogastroenterology; 2014 May; 61(131):814-20. PubMed ID: 26176079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma.
    Scheithauer W; Kornek GV; Raderer M; Hejna M; Valencak J; Miholic J; Kovats E; Lang F; Funovics J; Bareck E; Depisch D
    Br J Cancer; 1999 Aug; 80(11):1797-802. PubMed ID: 10468299
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer.
    Morizane C; Okusaka T; Furuse J; Ishii H; Ueno H; Ikeda M; Nakachi K; Najima M; Ogura T; Suzuki E
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):313-9. PubMed ID: 18398614
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Weekly gemcitabine plus Epirubicin as effective chemotherapy for advanced pancreatic cancer: a multicenter phase II study.
    Neri B; Cini G; Doni L; Fulignati C; Turrini M; Pantalone D; Mini E; De Luca Cardillo C; Fioretto LM; Ribecco AS; Moretti R; Scatizzi M; Zocchi G; Quattrone A
    Br J Cancer; 2002 Aug; 87(5):497-501. PubMed ID: 12189543
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study).
    Ozaka M; Matsumura Y; Ishii H; Omuro Y; Itoi T; Mouri H; Hanada K; Kimura Y; Maetani I; Okabe Y; Tani M; Ikeda T; Hijioka S; Watanabe R; Ohoka S; Hirose Y; Suyama M; Egawa N; Sofuni A; Ikari T; Nakajima T
    Cancer Chemother Pharmacol; 2012 May; 69(5):1197-204. PubMed ID: 22249272
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer.
    Oh DY; Cha Y; Choi IS; Yoon SY; Choi IK; Kim JH; Oh SC; Kim CD; Kim JS; Bang YJ; Kim YH
    Cancer Chemother Pharmacol; 2010 Feb; 65(3):527-36. PubMed ID: 19578850
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma.
    Duffy A; Kortmansky J; Schwartz GK; Capanu M; Puleio S; Minsky B; Saltz L; Kelsen DP; O'Reilly EM
    Ann Oncol; 2008 Jan; 19(1):86-91. PubMed ID: 17878176
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy.
    Reni M; Cereda S; Mazza E; Passoni P; Nicoletti R; Balzano G; Zerbi A; Arcidiacono PG; Staudacher C; Di Carlo V
    Am J Clin Oncol; 2008 Apr; 31(2):145-50. PubMed ID: 18391598
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3).
    Go SI; Lee SC; Bae WK; Zang DY; Lee HW; Jang JS; Ji JH; Kim JH; Park S; Sym SJ; Yang Y; Jeon SY; Hwang IG; Oh SY; Kang JH
    Eur J Cancer; 2021 Nov; 157():21-30. PubMed ID: 34464782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.